Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use

mAbs

Volumn 6, Issue 2, 2014, Pages 547-555

  Stevens, Misty W ^a   Tawney, Rachel L ^a,b   West, C Michael ^b   Kight, Alicia D ^c   Henry, Ralph L ^a,c   Owens, S Michael ^a,b   Gentry, W Brooks ^a,b  

^a InterveXion Therapeutics LLC   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS   (United States)

Author keywords

Addiction; Bioequivalence; Chimeric antibody; Human; Methamphetamine; Monoclonal antibody; Pharmacokinetics

Indexed keywords

COMPLEMENT COMPONENT C1Q; METHAMPHETAMINE; METHAMPHETAMINE MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; IN VITRO STUDY; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MALE; NONHUMAN; RAT;

ADDICTION; BIOEQUIVALENCE; CHIMERIC ANTIBODY; HUMAN; METHAMPHETAMINE; MONOCLONAL ANTIBODY; PHARMACOKINETICS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; COMPLEMENT C1Q; HUMANS; IMMUNOTHERAPY; MALE; METHAMPHETAMINE; MICE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; SUBSTANCE-RELATED DISORDERS; TISSUE DISTRIBUTION;

EID: 84896501386     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27620     Document Type: Article

References (21)

1. Darracq L, Blanc G, Glowinski J, Tassin JP. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. J Neurosci 1998; 18:2729-39; PMID:9502830
2. Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin J-P. 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur J Neurosci 2004; 20:3073-84; PMID:15579162; http://dx.doi.org/10.1111/j.1460-9568. 2004.03805.x
3. Vocci FJ, Appel NM. Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 2007; 102(Suppl 1):96-106; PMID:17493058; http://dx.doi.org/10.1111/j.1360-0443.2007.01772.x
4. Gentry WB, Rüedi-Bettschen D, Owens SM. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin Pharmacol Ther 2010; 88:390-3; PMID:20668443; http://dx.doi.org/10.1038/clpt.2010.155
5. Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EC, Gentry WB, West M, Che Y, Carroll FI, Owens SM. Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine 2009; 27:7011-20; PMID:19800446; http://dx.doi.org/10.1016/j.vaccine.2009.09.072
6. Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol 2003; 461:119-28; PMID:12586207; http://dx.doi.org/10.1016/S0014-2999(03)01313-X
7. Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol 2006; 6:968-77; PMID:16644483; http://dx.doi.org/10.1016/j.intimp.2006.01.008
8. Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets 2011; 10:892-8; PMID:22229314; http://dx.doi.org/10.2174/187152711799219370
9. Hamilton RG. The Human IgG Subclasses. Baltimore, MD: Calbiochem-Novabiochem Corporation; 2001.
10. Labrijn AF, Buijsse AO, van den Bremer ETJ, Verwilligen AYW, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt. 1553
11. Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur J Pharmacol 2005; 521:86-94; PMID:16182279; http://dx.doi.org/10.1016/j.ejphar.2005.08.016
12. Carroll FI, Abraham P, Gong PK, Pidaparthi RR, Blough BE, Che Y, Hampton A, Gunnell M, Lay JO Jr., Peterson EC, et al. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem 2009; 52:7301-9; PMID:19877685; http://dx.doi.org/10.1021/ jm901134w
13. Alvarenga ML, Kikhney J, Hannewald J, Metzger AU, Steffens K-J, Bomke J, Krah A, Wegener A. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor. Anal Biochem 2012; 421:138-51; PMID:22085444; http://dx.doi.org/10.1016/j.ab.2011.10.039
14. Ramakrishnan M, Alves De Melo F, Kinsey BM, Ladbury JE, Kosten TR, Orson FM. Probing cocaine-antibody interactions in buffer and human serum. PLoS One 2012; 7:e40518; PMID:22859949; http://dx.doi.org/10.1371/journal.pone.0040518
15. Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab Dispos 2006; 34:906-12; PMID:16507651
16. Brecht ML, von Mayrhauser C, Anglin MD. Predictors of relapse after treatment for methamphetamine use. J Psychoactive Drugs 2000; 32:211-20; PMID:10908010; http://dx.doi.org/10.1080/02791072.2000.10400231
17. Bazin-Redureau MI, Renard CB, Scherrmann JM. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab′)2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 1997; 49:277-81; PMID:9231345; http://dx.doi.org/10.1111/j.2042-7158.1997.tb06795.x
18. Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, Günthard HF. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother 2006; 50:1773-9; PMID:16641449; http://dx.doi.org/10.1128/AAC.50.5.1773-1779.2006
19. Pierce MM, Raman CS, Nall BT. Isothermal titration calorimetry of protein-protein interactions. Methods 1999; 19:213-21; PMID:10527727; http://dx.doi.org/10.1006/meth.1999.0852
20. Hendrickson H, Laurenzana E, Owens SM. Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. AAPS J 2006; 8:E709-17; PMID:17233534; http://dx.doi.org/10.1208/aapsj080480
21. Rivière GJ, Byrnes KA, Gentry WB, Owens SM. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J Pharmacol Exp Ther 1999; 291:1220-6; PMID:10565845